Zemplar - General Information:

Zemplar is a synthetic vitamin D analog. Zemplar has been used to reduce parathyroid hormone levels. Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Pharmacology:

Secondary hyperparathyroidism is characterized by an elevation in parathyroid hormone (PTH) associated with inadequate levels of active vitamin D hormone. The source of vitamin D in the body is from synthesis in the skin and from dietary intake. Vitamin D requires two sequential hydroxylations in the liver and the kidney to bind to and to activate the vitamin D receptor (VDR). The endogenous VDR activator, calcitriol [1,25(OH)2 D3], is a hormone that binds to VDRs that are present in the parathyroid gland, intestine, kidney, and bone to maintain parathyroid function and calcium and phosphorus homeostasis, and to VDRs found in many other tissues, including prostate, endothelium and immune cells. VDR activation is essential for the proper formation and maintenance of normal bone. In the diseased kidney, the activation of vitamin D is diminished, resulting in a rise of PTH, subsequently leading to secondary hyperparathyroidism and disturbances in the calcium and phosphorus homeostasis.1 Decreased levels of 1,25(OH)2 D3 have been observed in early stages of chronic kidney disease. The decreased levels of 1,25(OH)2 D3 and resultant elevated PTH levels, both of which often precede abnormalities in serum calcium and phosphorus, affect bone turnover rate and may result in renal osteodystrophy. An in vitro study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A at concentrations up to 50 nM (21 ng/mL).

Zemplar for patients

The patient or guardian should be informed about compliance with dosage instructions, adherence to instructions about diet and phosphorus restriction, and avoidance of the use of unapproved nonprescription drugs. Phosphate-binding agents may be needed to control serum phosphorus levels in patients, but excessive use of aluminum containing compounds should be avoided. Patients also should be informed about the symptoms of elevated calcium.

Zemplar Interactions

Paricalcitol is not expected to inhibit the clearance of drugs metabolized by cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP2E1 or CYP3A nor induce the clearance of drugs metabolized by CYP2B6, CYP2C9 or CYP3A.

A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-¥.

Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole.

Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.

Zemplar Contraindications

Zemplar Capsules should not be given to patients with evidence of vitamin D toxicity, hypercalcemia, or hypersensitivity to any ingredient in this product .

Additional information about Zemplar

Zemplar Indication: For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Mechanism Of Action: Zemplar is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Paricalcitol
Synonyms: Not Available
Drug Category: Not Available
Drug Type: Small Molecule; Approved; Investigational
Other Brand Names containing Paricalcitol: Zemplar;
Absorption: Well absorbed
Toxicity (Overdose): Not Available
Protein Binding: 99.8% (bound to plasma proteins)
Biotransformation: Metabolized by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4
Half Life: 4 to 6 hours
Dosage Forms of Zemplar: Solution Intravenous
Chemical IUPAC Name: (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
Chemical Formula: C27H44O3
Paricalcitol on Wikipedia: Not Available
Organisms Affected: Humans and other mammals

Bookmark or Share this page


»Get link codes for this page«
(HTML/BB code)



Search by name browsing our [A-Z] index:

ABCDEFGHI
JKLMNOPQR
STUVWXYZ

Search by Categories:

See a list of all drugs for sale »

Top5 meds in current month:

*based on number of page views on Flexyx

Visit our friends:

brand and generic ed pills Russian Scientific Center for Restorative Traumatology and Orthopaedics in the name of academician G.A.Ilizarov

Related News

Thu, 05 Apr 2012
Paricalcitol (Zemplar) - Drug Dosage and Side Effects - Healthline
What is this medicine. What may interact with this medicine. How should I use this medicine. What side effects may I notice from receiving this medicine. What should I tell my health care provider before I take this medicine.
Source: www.healthline.com »

Thu, 29 Mar 2012
Paricalcitol-1 (Zemplar) - Drug Dosage and Side Effects - Healthline
What is this medicine. How should I use this medicine. What should I tell my health care provider before I take this medicine. What may interact with this medicine. What if I miss a dose.
Source: www.healthline.com »

Fri, 20 Jan 2012
Zemplar Soft Capsules 1, 2 and 4 mcg - Summary of Product Characteristics (SPC) - electronic ...
System Organ Class. The electronic Medicines Compendium (eMC) contains information about UK licensed medicines. Abbott Laboratories Limited. Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE, UK. Often several companies will market medicines with the same active ingredient.
Source: www.medicines.org.uk »



Thanks for visiting us!